Enhanced external counterpulsation (EECP) is a noninvasive, non-pharmacologic intervention proven to increase nitric oxide bioavailability in patients with coronary artery disease. Although EECP showed short-term effects in improving coronary flow in patients with coronary slow flow, whether such improvement is durable remains uncertain, and the relationships between such improvement and changes in multiple organ functions as well as inflammatory markers have not been elucidated. The purpose of this study will be to evaluate the potential clinical benefits of EECP on organ function and proinflammatory cytokine concentrations during post-acute sequela of cardiovascular surgery.

开始日期2025-12-31

申办/合作机构

南京医科大学

[+1]

NCT06356688

/ Not yet recruiting临床2期IIT

A Clinical Study on the Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection and Cisplatin Combined with Cadonilimab As a Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma: a Single-Arm, Single-Center, Prospective Clinical Trial (POINTS Trial)

The purpose of this study is to investigate the efficacy and safety of neoadjuvant treatment of locally advanced esophageal squamous carcinoma with a PD-1/CTLA-4 bispecific antibody (Cadonilimab) in combination with platinum-containing chemotherapy (Paclitaxel Polymeric Micelles for Injection combined with Cisplatin). Includes pathologic complete remission rates (pCR rates) after 2-4 cycles of Cadonilimab combination chemotherapy. The objective remission rate (ORR), major pathologic remission rate (MPR), R0 resection rate and 2-year overall survival (OS) and progression-free survival (OS) rates, and safety of neoadjuvant treatment of locally advanced esophageal squamous carcinoma with Cadonilimab combined with chemotherapy.

开始日期2025-04-20

申办/合作机构

南京医科大学第一附属医院

NCT06838520

/ Not yet recruitingN/AIIT

A Prospective Study on the Impact of Androgen Deprivation Therapy (ADT) and Androgen Receptor Pathway Inhibitors (ARPI) on Bone Loss in Prostate Cancer Patients

This study aims to assess the impact of Androgen Deprivation Therapy (ADT) and Androgen Receptor Pathway Inhibitors (ARPI) on bone quality in patients with prostate cancer. Patients undergoing ADT for prostate cancer often experience adverse effects such as decreased bone density and increased fracture risk. While ARPIs are emerging as novel therapeutic agents, their effects on bone quality remain unclear. This study will compare patients receiving combined ADT and ARPI therapy with those receiving ADT alone, evaluating changes in bone density, bone microarchitecture, and bone metabolic markers. The findings will help optimize treatment strategies for prostate cancer patients, reduce the risk of osteoporosis, and improve overall quality of life.

开始日期2025-04-01

申办/合作机构

南京医科大学第一附属医院

100 项与南京医科大学第一附属医院相关的临床结果

登录后查看更多信息

0 项与南京医科大学第一附属医院相关的专利（医药）

登录后查看更多信息

13,033

项与南京医科大学第一附属医院相关的文献（医药）

2025-12-31·RENAL FAILURE

Delta corticomedullary apparent diffusion coefficient on MRI as a biomarker for prognosis in IgA nephropathy

Article

作者: Jiang, Ling ; Zhang, Chengning ; Zhang, Bo ; Yuan, Yanggang ; Sun, Bin ; Lu, Fang ; Xing, Changying ; Huang, Zhimin ; Mao, Huijuan ; Qian, Li ; Duan, Suyan ; Zeng, Ming ; Pan, Ying ; Wang, Zitao ; Zhang, Yudong

OBJECTIVES:

To explore the association of the cortico-medullary difference in apparent diffusion coefficient (ΔADC) with clinicopathological parameters of disease activity at the time of biopsy, and with the prognositic risk stratification in IgA nephropathy (IgAN) patients.

METHODS:

We included 112 patients with biopsy-proven IgAN who measured ΔADC. Patients underwent a kidney biopsy and diffusion-weighted magnetic resonance imaging within one week of the biopsy. Clinicopathological characteristics were compared according to different ΔADC levels. The effect of ΔADC on eGFR and kidney fibrosis was explored using multivariate regression and ROC analysis. An individual's 5-year risk probability of progressing to ESKD or decreasing of eGFR > 50% was calculated by the guidelines-recommended international risk-prediction tool in IgAN. The effect of ΔADC on prognostic risk stratification was assessed. Net reclassification improvement (NRI) was used to evaluate the model performance.

RESULTS:

The average ΔADC was 168.89 ± 85.1 x10^-6 mm²/s. ΔADC levels decreased significantly with increasing chronic kidney disease (CKD) stages (p = 0.0038). Spearman correlation analysis revealed that ΔADC was positively correlated with eGFR, hemoglobin, serum albumin, while negatively correlated with levels of serum creatine (Scr), blood urea nitrogen (BUN), T score of Oxford classification and Lee grades (p < 0.05). Moreover, we showed that ΔADC was independently associated with eGFR (β = 0.04, 95% CI = [0.003, 0.077], p = 0.033) demonstrated by a backward stepwise multivariate linear regression analysis. Besides, ΔADC, a combination of ΔADC and eGFR showed an AUC of 0.776 (60% sensitivity and 85.3% specificity) and an AUC of 0.875 (100% sensitivity and 69.6% specificity) respectively for evaluating kidney interstitial fibrosis (IF) severity. Furthermore, ΔADC showed an AUC of 0.792 (95% CI 0.677-0.906) for differentiating higher progression risk categories from lower categories (specificity = 91.6%, sensitivity = 58.8%). The low-ΔADC group (≤ median value 167.1 × 10^-6 mm²/s) was associated with 7.509-fold higher likelihood of higher progression risk compared to the high-ΔADC group (>167.1 × 10^-6 mm²/s) in a fully-adjusted model. And reclassification analyses confirmed that the final adjusted model improved NRI.

CONCLUSIONS:

ΔADC was significantly associated with kidney function and enabled a reliable evaluation of kidney IF severity in IgAN patients. Low ΔADC can predict a high 5-year kidney progression risk in IgAN, independent of important clinical factors. Moreover, the predictive ability to identify patients at high risk of severe kidney fibrosis and adverse progression estimates with satisfactory accuracy, facilitating ΔADC a promising and noninvasive tool in complementarily evaluating disease activity and the prognostic risk stratification in patients with IgAN.

2025-12-31·RENAL FAILURE

Role of microvascular pericyte dysfunction in antibody-mediated rejection following kidney transplantation

作者: Ju, Xiaobing ; Xu, Jie ; Han, Zhijian ; Tan, Ruoyun ; Chen, Hao ; Sun, Li ; Fei, Shuang ; Pu, Junyan ; Gu, Min ; Wang, Zijie ; Tao, Jun

ObjectiveTo investigate the role of microvascular pericyte dysfunction in antibody-mediated rejection (ABMR) of transplanted kidneys.MethodsA total of 160 patients who underwent kidney transplantation in our hospital from 2004 to 2020 were enrolled, divided into 4 groups: ABMR group (n = 79), TCMR group (n = 20), mixed rejection group (n = 25) and control group (n = 36).Postoperative renal function indicators were compared, and immunohistochem. and immunofluorescence staining was performed on graft tissues and mice models using the pericyte marker PDGFR-β.An in vitro pericyte dysfunction model was co-cultured with vascular endothelial cells for functional assessment through Western blotting, PCR, and wound healing tests.KEGG pathway anal. from the GEO database identified gene expression changes in pericytes, which were further analyzed using electron microscopy and Western blot techniques.ResultsThere were statistically significant differences in creatinine, urea nitrogen, urine protein, and eGFR among the groups over time, with ABMR displaying the poorest outcomes.Immunohistochem. revealed lower pericyte expression in ABMR, which was confirmed in mouse model studies showing reduced PDGFR-β expression in ABMR.KEGG anal. highlighted decreased autophagy in pericyte dysfunction, supported by electron microscopy and Western blot findings indicating reduced autophagy and pericyte damage, which could be reversed by chloroquine.ConclusionABMR episodes worsened the long-term prognosis of transplanted kidneys. pericyte dysfunction appears to be one of the crucial causes of poor prognosis in ABMR patients.In vitro studies demonstrated that dysfunction of microvascular pericytes can result in damage to vascular endothelial cells, with autophagy impairment being a significant mechanism contributing to pericyte dysfunction.

2025-12-31·PHARMACEUTICAL BIOLOGY

Overview of current research on traditional Chinese medicine in skin disease treatment: a bibliometric analysis from 2014 to 2024

Review

作者: Cai, Yuan ; Jiang, Feng ; Bao, Yunlei ; Li, Lin ; Zeng, Ni ; Wen, Xue ; Zheng, Chenjie ; Sun, Nana ; Wu, Chuyan ; Zhang, Lanfang ; Li, Yuan

CONTEXT:

Recent research has revealed significant advancements in the field of traditional Chinese medicine (TCM) for skin diseases. However, there is a lack of visualization analysis within this research domain.

OBJECTIVE:

To analyze the research directions and advancements in TCM research in skin diseases.

MATERIALS AND METHODS:

Publications related to TCM in skin diseases from 2014 to 2024 were searched on the Web of Science Core Collection (WoSCC), VOSviewer, CiteSpace, and the R package "bibliometrix" were employed to visualize and analyze the retrieved data.

RESULTS:

The study included 527 articles published in 25 countries. The number of publications consistently increased from 2014 to 2024. The Guangzhou University of Chinese Medicine was the most noteworthy institution in this field. Among the journals in this domain, the Journal of Ethnopharmacology was the most popular, and most frequently co-cited journal. Chuanjian Lu published the most papers and Yin-Ku Lin was the most frequently co-cited author. Among keywords, "psoriasis" appeared the most frequently. Additionally, several emerging research hotspots were identified, indicating the transition from traditional Chinese therapies to investigations of the molecular interactions and network pharmacology of Chinese herbs in treatment of skin diseases over the past decade.

DISCUSSION AND CONCLUSION:

This visualization analysis summarizes the research directions and advancements in TCM research on skin diseases. It presents a comprehensive examination of the latest research frontiers and trends and serves as a valuable reference for scholars engaged in the study of TCM research.

项与南京医科大学第一附属医院相关的新闻（医药）

2024-02-09

·今日头条

特别推荐 | 8分钟重温2023年《肠·道》演讲金句

14个学术主题，30位知名专家，547分钟时长，汇成了2023年《肠·道》演讲。作为“肠道专业人士的招牌演讲”，《肠·道》演讲已走过了6年。截至2023年12月31日，热心肠研究院累计邀请160位讲者，分享了他们对肠道产学研领域的真知灼见与实践感悟。如今，我们集锦2023年《肠·道》演讲的专家金句制成此视频，在新春来临之际，特别献给那些深耕肠道的业界同仁与关注肠道健康的朋友！我们关注微生态，也关注同一健康蓝灿辉热心肠智库专家热心肠生物技术研究院董事长兼院长我们大家都在关注微生态，尤其是肠道微生态。应该来说就是我们站在一个生态系统的这种角度，把中国传统的天人合一与西方现在用生态的理念去看人体、看自然环境，能够吻合和统一起来。吴崇明热心肠智库专家天津中医药大学研究员在每个人的肠道都定植一个由成百上千种肠道细菌构成的茂密森林，如何能够定向地将变异的菌群恢复到正常状态，使我们的健康得到改善，这是一个重要的问题。蒋超热心肠智库专家浙江大学生命科学研究院研究员暴露组作为一个相对来说比较新的领域，其实它是有非常重要的作用。“同一健康”的概念里面强调，我们必须得对人，还有环境以及动物的健康进行统一的研究。褚海燕热心肠智库专家中国科学院南京土壤研究所研究员过去我们把土壤当成惰性的化学介质，在土壤上修路、盖房子、种庄稼。实际上土壤是有生命的，土壤中的生物赋予了土壤的生命性。张志刚热心肠智库专家云南大学研究员我们就提出这样一个理念，关注全球的水资源的健康和水体的健康，也就是关注我们的肠道的健康，最终也就是关注我们自己的健康。王敬文热心肠智库专家复旦大学生命科学学院研究员思想家魏源曾经说过一句话：“师夷长技以制夷”。我们现在也就是正在从通过对虫媒肠道微生物的学习，最终研发出如何控制蜱虫传病的方法。我们关注人的肠道，也关注动物的肠道于政权热心肠智库专家中国农业大学生物学院教授肠道干细胞的两类调控因子，一类是肠道干细胞内源性的调控因子，一类是间充质微环境的调控因子，肠道干细胞的功能于肠道稳态至关重要。梁冠翔热心肠智库专家清华大学医学院助理教授到至今为止，其实我们一直没有证据能显示，妊娠期的子宫内有活性的微生物组，在不断地扩增、复制、释放活性的代谢产物。左涛热心肠智库专家中山大学附属第六医院研究员肠道病毒作为肠道细菌的伙伴，其在人体肠道中的存在数量是细菌总量的1~10倍，目前60%以上的人类的肠道病毒其实还从未被解析过。王修启热心肠智库专家华南农业大学动物科学学院研究员通过我们的研究发现，胞外谷氨酸与细胞膜上的G蛋白偶联受体FZD7、EGFR、IR结合，可以激活β-catenin和mTORC1信号，增加蛋白质的合成，促进猪肠道干细胞扩增，调控肠道健康。陶诗煜热心肠智库专家华中农业大学动物科技学院副研究员从健康仔猪分离的特定乳酸菌及其分泌的胞外囊泡，通过控制炎症反应减轻腹泻症状，其中巨噬细胞的表型转化是缓解腹泻的必要条件。孔祥峰热心肠智库专家中国科学院亚热带农业生态研究所研究员日粮添加胆汁酸可以保护断奶仔猪的肝脏，促进肠道潜在有益菌的繁殖，促进正常体重仔猪结肠发育，减轻IUGR仔猪结肠损伤，改善它的通透性并改善结肠微生物的平衡。武圣儒热心肠智库专家西北农林科技大学动物科技学院副教授我们的团队过去、现在和将来都将以瘤胃微生物代谢为核心，整合胰腺淀粉酶分泌、肠道微生物代谢以及乳腺和肝脏代谢的相关研究，为提高奶畜的饲料转化效率和泌乳效率持续开展攻关研究。我们关注疾病治疗，也关注健康管理卞兆祥热心肠智库专家香港浸会大学中医药学院讲座教授肠道菌群的失常，这里面可以表现出来的是肠道菌群引起的代谢物质失常，再影响到肠道局部跟肠道的周身体系的症状。我们说通过改善肠道菌，可以让肠道不要那么激动。陈宁热心肠智库专家北京大学人民医院主任医师环境究竟是如何导致了肠道菌群的失衡？这仍然是我们在研究IBD发病机制当中的一个未解之谜。我和我的团队进行IBD发病机制的研究当中，我们把目光锁定了口腔。何丛南昌大学第一附属医院副主任医师我们又在想，肠道菌群失衡是通过何种机制促进胰腺炎的重症化呢？我们将目标聚焦于NLRP3炎症小体。林国乐热心肠智库专家北京协和医院主任医师五步筑牢我们抗肠癌的一个防线——防、筛、诊、治、康：在防和筛方面，我们提出一个新的理念叫数字药丸；在康复方面，我提出一个新的理念就是肠癌术后五年大学计划。刘志刚热心肠智库专家西北农林科技大学食品科学与工程学院教授限制饮食是具有延缓衰老的潜力的，我们将继续致力于探索能够模拟卡路里限制益处的饮食干预方式，并且探索多种方案的组合。王宇浩热心肠智库专家浙江大学转化医学研究院研究员通过人为改变肠道菌群的组成，比如服用某些能够提高 Snhg9 表达的益生菌，来降低肠道的脂质吸收效率，从而达到减肥的目的。张家超热心肠智库专家海南大学食品科学与工程学院通过高膳食纤维饮食模式，选择性地来激发肠道本地菌群与益生菌展开一个竞争性的共进化，这种方式能够有效地提升双歧杆菌的肠道适应性，也证明了饮食干预策略来驯化益生菌的一个可行性。郑晓皎热心肠智库专家上海交通大学医学院附属第六人民医院研究员在最近几年，我们一直把目光聚焦在一类非12羟基胆汁酸，也就是猪胆酸上，发现猪胆酸可以通过多靶点来调控糖脂代谢和免疫。陈连民热心肠智库专家南京医科大学/江苏省人民医院教授要关注心血管代谢健康，可能要更多地关注饮食的健康以及肠道微生态的健康，而不用太去计较我们与生俱来的遗传的先天性决定因素。我们关注新理念新技术，也关注产业转化王琰热心肠智库专家中国医学学科学院药物研究所研究员当肠道菌群遇见药物的时候，实际上是开辟了药学研究的一个新领域，并助力我们认知药物在临床的个性化治疗。刘宏伟热心肠智库专家中国科学院微生物研究所研究员中药的现代化，必须要从肠道微生物的角度去认识和挖掘，阐明中药通过肠道微生物发挥重要作用的机制，必将为中药现代化做出重要的贡献。陈启仪热心肠智库专家上海市第十人民医院副主任医师在国际当中，复杂性、难治性、慢性、功能障碍性疾病，炎症性或者是肠道为主的肠道外疾病，肠菌移植都在临床逐渐的应用。作为长期有效的、能够走长远的一条路来讲，我们可能会将药品的研发作为一个新的选择。崔伯塔热心肠智库专家南京医科大学第二附属医院副教授让菌群移植像输血一样安全高效，从很粗的菌群的移植到洗涤菌群，到将来也可能精准化菌群移植的输注，这是未来的一个发展的趋势。郝梓凯热心肠智库专家北京理工大学生命学院副教授我们发现“月宫一号”可以最大限度地保持影响微生物-肠-脑轴的因素基本不变，并且最大限度地避免非精神因素对微生物-肠-脑轴的影响，是挖掘精神益生菌的理想实验平台。张佳中国科学院青岛生物能源与工程研究所副研究员目前益生菌的快检技术应用的范围会越来越广泛，包括食品、医药、农业等等。SCIVVS技术作为一项具有广泛应用前景的质检技术，必将为人类健康保驾护航。苏晓泉热心肠智库专家青岛大学计算机科学技术学院教授利用大数据和搜索引擎，我们提供了菌群检测中的一些问题的新的解决方案。所以大模型的发展有可能让我们重新认识菌群，获得一些不一样的理解。 Johanna Maukonen IFF Health全球临床研究与转化总监无论益生菌还是下一代益生菌，都需要更多的作用机制数据，来真正获得转化的潜力，还会有很多伟大的事情将要发生。未来会有什么机遇呢？请持续关注！

微生物疗法

2023-06-13

·BioSpace

A Chinese Neurosurgical Journal Study Presents Consensus on the Management of Aneurysmal Subarachnoid Hemorrhage-Related Hydrocephalus

Neurosurgeons from China review the latest literature from across the world to develop the consensus guidelines BEIJING, June 13, 2023 /PRNewswire/ -- Aneurysmal subarachnoid hemorrhage-related hydrocephalus (aSAH-H) is a clinical syndrome that leads to excessive accumulation of cerebrospinal fluid (CSF) and ventricle enlargement in the brain. aSAH-H is a complex pathophysiological syndrome, leadingto cognitive impairment and neurological damage. Acute hydrocephalus (less than 3 days of aSAH) can result in a fatal cerebral hernia, whereas chronic hydrocephalus (more than 3 days of aSAH) can adversely affect a patient's quality of life. Despite the complexity of this condition, there is a lack of diagnostic criteria and treatment protocol for aSAH-H, in China and abroad. Moreover, the lack of consensus among clinicians on the preferred treatment for aSAH-H calls for an urgent need for consistent standards. Prof. Shuo Wang from the Department of Neurosurgery at Beijing Tiantan Hospital, Capital Medical University, recently led an expert group from China to review and compose a consensus on the management of aSAH-H, based on the latest literature. The study was published in volume 9 of the Chinese Neurosurgical Journal on March 20, 2023. Dr. Hua Lu from the Department of Interventional Neuroradiology at Jiangsu Province Hospital along with Prof. Wang are the corresponding authors of this study. "Hydrocephalus is a common complication following aSAH and currently, the diagnosis and treatment of aSAH-H is clouded by a lack of clarity and inconsistency of standards. We wanted to make definite progress toward removing the ambiguity tied to its treatment," explains Prof. Wang. In terms of occurrence, the experts identified that aSAH-H is determined by the location of the aneurysm, intraventricular hemorrhage, and volume of the subarachnoid hemorrhage. Disturbances in CSF circulation drive the pathogenesis of aSAH-H, enlarge the ventricular system, and damage the brain's white matter. The experts concluded that age, volume of subarachnoid hemorrhage, the location and size of aneurysms are risk factors related to the occurrence of aSAH-H. The consensus states that the standard-of-care approach to diagnosis should include reviewing a patient's history of aSAH-H, identifying its clinical manifestations, and a head computed tomography scan to detect abnormal enlargement of the ventricles. Moreover, the consensus states that aSAH-H treatment should be aimed at releasing excessive intracranial pressure or addressing pathological changes to prevent further damage and loss of neurological function. This can include medications inhibiting CSF secretion or surgical interventions, such as CSF drainage, CSF shunt surgery, and CSF intracranial diversion. Furthermore, the consensus guideline recommends external ventricular drainage and ensuring the safe removal of the CSF drainage tube in the case of acute hydrocephalus. A ventriculoperitoneal shunt is recommended for cases of chronic hydrocephalus. The effectiveness of a shunt procedure can be confirmed with a positive lumbar puncture preceding surgery. Lastly, the consensus suggests measures to minimize postoperative complications. It recommends strict aseptic surgical procedures, anti-siphon and pressure-adjustable shunt catheters, monitoring of clinical manifestations, and use of imaging and laboratory examinations for management. Evincing hope about this development, Prof. Wang says, "This expert consensus applies to adults, but it's a good reference point for clinical diagnosis and treatment. Further research will certainly refine the process of aSAH-H diagnosis and treatment." Reference Title of original paper: Chinese expert consensus on the management of aneurysmal subarachnoid hemorrhage- related hydrocephalus Journal: Chinese Neurosurgical Journal DOI View original content to download multimedia: SOURCE Chinese Neurosurgical Journal

2022-11-23

·PRNewswire

Jiangsu Traditional Chinese Medicine International Exchange Conference kicked off in Nanjing

NANJING, China, Nov. 23, 2022 /PRNewswire/ -- On November 21st, the "Jiangsu Traditional Chinese Medicine International Exchange Conference" jointly sponsored by the Foreign Affairs Office of Jiangsu Provincial People's Government and Jiangsu Health Commission kicked off in Nanjing. The theme of the conference is "Let the World Know Jiangsu Traditional Chinese Medicine", according to the organizing committee. Hu Gang, Vice-Chairman of the Jiangsu Provincial Committee of the CPPCC and President of Nanjing University of Chinese Medicine (NJUCM), said in his speech that Chinese medicine is the treasure of ancient Chinese science and the key to the treasure house of Chinese civilization. Jiangsu TCM International Exchange Conference is a powerful measure to link domestic and international markets and resources, and expand the international influence of Jiangsu Traditional Chinese Medicine, which provides new thinking and direction for Chinese medicine to serve the global health cause. Dr. Mary Faria, President & CEO of AOMA Graduate School of Integrative Medicine, said in a video speech that AOMA Graduate School of Integrative Medicine has established a good cooperative partnership with the Foreign Affairs Office of Jiangsu Provincial People's Government, Jiangsu Province Hospital of Chinese Medicine and NJUCM. Through joint efforts to build Jiangsu Overseas Qihuang Talent Training Project, international talents of traditional Chinese medicine have been trained, sincere humanities exchanges have been promoted, the spread of traditional Chinese medicine around the world has been promoted, and deep friendship has been established. It is hoped that all sides will work together to build a platform for international exchanges and cooperation of traditional Chinese medicine and promote deeper exchanges and cooperation between China and the United States in the field of health care. During the opening ceremony, the icon of Jiangsu TCM, the little Shennong, was launched. The world premiere ceremony of the first Chinese and English version of Chinese medicine comic book Little Shennong's Herbal Adventure in China was held; the collection of overseas book donation activities of Little Shennong's Herbal Adventure was broadcast; the awarding ceremony of the Feeling the Pulse of TCM with Z Generation English short video contest for exploring Chinese medicine was held; NJUCM and Mae Fah Luang University, Sunsuria Group of Malaysia and Instituto Piaget held the signing ceremony of TCM "going global" projects. NJUCM, the national "Double First-class" discipline construction university, as the core strength in Jiangsu Provincial Chinese Medicine development, has been in the forefront of facilitating the internationalization of Chinese medicine. Over the last sixty plus years, NJUCM with its affiliated hospitals has trained more than 30,000 international students. NJUCM world-renowned alumni include "The Father of European Chinese Medicine" Giovanni Maciocia, "The Father of Australian Chinese Medicine Legalization" Lin Tzi-Chiang, etc. NJUCM has established two Confucius Institutes for Traditional Chinese Medicine and eight overseas Chinese Medicine Centers. It has been designated as WHO Collaborating Center for Traditional Chinese Medicine for ten terms consecutively. The university has been selected as the first batch of National Base of Chinese Medicine Service Trade, and has established "Belt and Road" Chinese Medicine International Collaboration Base. It has the Chinese medicine clinics that have been the first to get the ISO 9001 certification. NJUCM has contributed greatly in facilitating Chinese medicine into the mainstream medical education system in Europe, and has dedicated to bringing health and well-being to people all over the world by using the advantages of traditional Chinese medicine. SOURCE The Organizing Committee of Jiangsu Traditional Chinese Medicine International Exchange Conference

100 项与南京医科大学第一附属医院相关的药物交易

登录后查看更多信息

100 项与南京医科大学第一附属医院相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

或

查看完整样例数据

管线布局

2025年03月26日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

临床前

临床1期

临床2期

其他

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

Mesothelin CAR-T cell therapy(Shenzhen BinDeBio Ltd.) ( MSLN )	胃癌更多	临床2期
亚叶酸/氟尿嘧啶 ( TYMS )	局部晚期胰腺腺癌更多	临床2期
褐藻多糖硫酸酯 ( CLEC-2 x CTNNB )	幽门螺杆菌感染更多	临床1/2期
UTAA09/17 ( CD19 )	难治性B细胞淋巴瘤更多	临床1期
Universal NK cell(Jiangsu Provincial People's Hospital) ( CD70 )	复发性血液恶性肿瘤更多	早期临床1期